Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
16.66 USD | +2.18% | -0.92% | -46.77% |
Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
Apr. 22 | Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada | MT |
Business Summary
Number of employees: 598
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Medicines
100.0
%
| 517 | 100.0 % | 726 | 100.0 % | +40.45% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 517 | 100.0 % | 726 | 100.0 % | +40.45% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Mark Schneyer
DFI | Director of Finance/CFO | 50 | 20-05-27 |
Benir Ruano
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-31 |
Sanjeev Pathak
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Brendan Teehan
COO | Chief Operating Officer | 56 | 18-06-30 |
Ponni Subbiah
CTO | Chief Tech/Sci/R&D Officer | - | 19-09-30 |
- | - | ||
Kimberly Manhard
PRN | Corporate Officer/Principal | 64 | Jan. 29 |
Kevin Oliver
PRN | Corporate Officer/Principal | - | 23-07-09 |
Holly Valdiviez
SAM | Sales & Marketing | - | 22-03-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 15-12-10 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 15-11-24 |
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Don Soland
BRD | Director/Board Member | 65 | 15-03-19 |
Laura Brege
BRD | Director/Board Member | 66 | 08-04-30 |
Stephen Biggar
CHM | Chairman | 53 | 13-01-21 |
James Daly
BRD | Director/Board Member | 63 | 16-01-10 |
Director/Board Member | 66 | 20-09-28 | |
Adora Ndu
BRD | Director/Board Member | 43 | 22-10-09 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 164,771,521 | 163,859,371 ( 99.45 %) | 0 | 99.45 % |
Company contact information
ACADIA Pharmaceuticals, Inc.
12830 El Camino Real Suite 400
92130-3331, San Diego
+858 558 2871
http://www.acadia.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.91% | 2.69B | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+47.53% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- ACAD Stock
- Company ACADIA Pharmaceuticals Inc.